



GAMBIA HPV DEMONSTRATION VACCINE SUPPORT
This Decision Letter sets out the Programme Terms of a Programme.

| 1. Country: Gambia | | | | | | | | | | | | | | | | |
|--|-------------|-------------|--------------------|--------------------|---------------------|-------------|------------|-------------|-----------|-------------|------------|-------------|-------------------------------|-------------|-------------|-------------|
| 2. Vaccines Grant Number: 1415-GMB-19b-X Cash Support Grant Number: 1415-GMB-24a-Y | | | | | | | | | | | | | | | | |
| 3. Date of Decision Letter: 12 February 2014 | | | | | | | | | | | | | | | | |
| 4. Date of the Partnership Framework Agreement: 03 February 2014 | | | | | | | | | | | | | | | | |
| 5. Programme Title: HPV Demonstration Programme | | | | | | | | | | | | | | | | |
| 6. Vaccine type: HPV | | | | | | | | | | | | | | | | |
| 7. Preferred product presentation and formulation of vaccine: HPV Quadrivalent, 1 dose(s) per vial, LIQUID | | | | | | | | | | | | | | | | |
| 8. Programme Duration¹: 2014 - 2015 | | | | | | | | | | | | | | | | |
| 9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement): | | | | | | | | | | | | | | | | |
| <table border="1"> <thead> <tr> <th></th> <th>2014</th> <th>2015</th> <th>Total²</th> </tr> </thead> <tbody> <tr> <td>HPV vaccines (US\$)</td> <td>US\$102,500</td> <td>US\$90,000</td> <td>US\$192,500</td> </tr> <tr> <td>Cash (\$)</td> <td>US\$170,000</td> <td>US\$25,000</td> <td>US\$195,000</td> </tr> <tr> <td>Total Programme Budget (US\$)</td> <td>US\$272,500</td> <td>US\$115,000</td> <td>US\$387,500</td> </tr> </tbody> </table> | | 2014 | 2015 | Total ² | HPV vaccines (US\$) | US\$102,500 | US\$90,000 | US\$192,500 | Cash (\$) | US\$170,000 | US\$25,000 | US\$195,000 | Total Programme Budget (US\$) | US\$272,500 | US\$115,000 | US\$387,500 |
| | 2014 | 2015 | Total ² | | | | | | | | | | | | | |
| HPV vaccines (US\$) | US\$102,500 | US\$90,000 | US\$192,500 | | | | | | | | | | | | | |
| Cash (\$) | US\$170,000 | US\$25,000 | US\$195,000 | | | | | | | | | | | | | |
| Total Programme Budget (US\$) | US\$272,500 | US\$115,000 | US\$387,500 | | | | | | | | | | | | | |
| 10. Vaccine Introduction Grant: Not applicable | | | | | | | | | | | | | | | | |

¹ This is the entire duration of the programme.

² This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):³*Vaccines:*

| Type of supplies to be purchased with GAVI funds in each year | 2014 | 2015 |
|---|-------------|------------|
| Number of HPV vaccines doses | 21,600 | 18,900 |
| Number of AD syringes | 22,800 | 19,800 |
| Number of safety boxes | 275 | 225 |
| Annual Amounts (US\$) | US\$102,500 | US\$90,000 |

Cash support:

| | |
|-----------------------|-------------|
| Cash Support by year | 2014 |
| Annual Amounts (US\$) | US\$170,000 |

12. Procurement agency: UNICEF SD**13. Self-procurement:** Not applicable**14. Co-financing obligations:** Not applicable**15. Operational support for campaigns:** Not applicable

16. Documents to be delivered for future disbursements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts. Further details can be found in the HPV Guidelines for Applications 2013.

| Reports, documents and other deliverables | Due dates |
|--|---|
| 1. A report of the evaluation of the HPV demonstration programme. 2. A copy of the approval by the local ethics committee, if a country determined that review and approval was required. 3. A report of the feasibility assessment of adolescent health interventions, with conclusions about what interventions are or are not feasible. 4. If an adolescent health intervention is identified for joint delivery with HPV vaccine, a description of the process by which the HPV vaccine delivery strategy will be modified and the steps required in planning and implementation with the district(s) and staff involved. 5. A summary of the activities completed and progress towards development of a national cervical cancer prevention and control strategy. | End of the first year (the first year starts when the first dose of the vaccine is administered). |
| 6. Financial reports for the GAVI HPV demonstration programme covering the year ended, in form and substance satisfactory to GAVI. | Within 3 months of the end of each Country's fiscal year. |
| 7. A summary report of year two delivery of HPV vaccinations, if not jointly delivered with adolescent health interventions. 8. If HPV was delivered jointly with adolescent health interventions, based on the year one feasibility assessment, an evaluation report of that delivery is required. 9. A copy of the developed or revised national cervical cancer prevention and control | End of second year (the first year starts when the first dose of the vaccine is administered and continues for twelve calendar months). |

³ This is the amount that GAVI has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

strategy.

17. Financial Clarifications: Not applicable

18. Other conditions: GAVI will disburse USD170,000 in the first year. In the second year, GAVI will disburse USD25,000 if the Country satisfies the following conditions: (i) the report of the feasibility assessment of adolescent health interventions has a conclusion that the interventions are feasible; and, (ii) the Country has submitted description of the process by which the HPV vaccine delivery strategy will be modified and the steps required in planning and implementation with the district(s) and staff involved.

On behalf of the GAVI Alliance

Signed by



Hind Khatib-Othman
Managing Director, Country Programmes

Date: 12 February 2014

